2 **Norregaard JC**, Hindsberger C, Alonso J, *et al.* Visual outcomes of cataract surgery in the United States, Canada, Denmark, and Spain. Report from the International Cataract Surgery Outcomes Study. *Arch Ophthalmol* 1998;**116**(8):1095–100.
3 **Busbee BG**, Brown MM, Brown GC, *et al.* Incremental cost-effectiveness of initial cataract surgery. *Ophthalmology* 2002;**109**(3):606–12.
4 **Brown MM**, Brown GC, Sharma S. *Evidence-based to value-based medicine*. Chicago: AMA Press, 2005.
5 **Anon**. Life expectancy in Europe. News-Medical.net, July 9, 2006. http://www.news-medical.net/?id=18747 (accessed 17 January 2007).
6 **Anon**. Social Security Online. Actuarial publications, period life tables, updated June 7, 2006. http://www.ssa.gov/OACT/STATS/table4c6.html (accessed 17 January 2007).
7 **Brown MM**, Brown GC. *Quality-of-life utility database*. Flourtown, PA: Center for Value-Based Medicine, 2006;**1**:514.

rRNA-based tests for chlamydial infection in trachoma

Robin Bailey

Trachoma, the worlds leading cause of preventable blindness, is the subject of worldwide control efforts via the SAFE (Surgery, Antibiotic Treatment, Facial Cleanliness and Environmental Improvement) strategy. The ''A'' component of this strategy antibiotic treatment of the active disease has been supported through the large scale donation of millions of doses of the antibiotic azithromycin by its manufacturers, Pfizer, for distribution in trachoma endemic areas by the International Trachoma Initiative.[1] Azithromycin, as a single 20 mg/kg oral dose is effective against *Chlamydia trachomatis* infection.[2] In the field the diagnosis of active trachoma may be made simply by examining the surface of the everted upper eyelid for clinical signs of trachoma: lymphoid follicles and inflammatory thickening.[3] Current recommendations are that communities in which the prevalence of active trachoma is greater than 10% of 1–9 year olds should be mass treated annually for three years.[4] So far, so good. A problem, however is that the clinical signs of trachoma are quite poorly predictive of the presence of ocular chlamydial infection. Wherever tests for infection have been carried out, there have been significant rates of mismatch between infection and clinical signs: infection without disease and disease without infection are very common. There are also examples of whole communities with substantial rates of active trachoma in whom not a single individual has been found to harbour *C trachomatis* infection,[5] and of communities where mass treatment has suppressed infection, but clinical signs of trachoma persisted at pre-treatment levels.[6] Distributing azithromycin repeatedly to such communities must be considered wasteful of scarce resources.

Thus there are at least three reasons why testing for infection in trachoma may be informative. Firstly it may tell us how to prioritise individuals or communities for treatment. Secondly it may indicate when treatment, or distribution ought to be discontinued, or resumed. Finally we may learn something useful about the biology of trachoma. In their paper, Yang *et al* present the first data using a commercial assay which detects chlamydial ribosomal RNA (rRNA) in subjects with trachoma (***see page 293***).[7] Because chlamydial rRNA, reflecting ribosomal activity, is typically present in infected cells at a multiplicity of hundreds to thousands of copies per chlamydial chromosome one would expect that, as demonstrated in their findings, rRNA based testing would be more sensitive than the more commonly applied Amplicor PCR, which detects the common chlamydial plasmid pCT typically present at a median multiplicity of about six per chromosome in ocular infection.[8]

The advent of rRNA based tests raises more questions in need of answering. Does the detection of rRNA without chlamydial DNA really indicate an infectious reservoir of epidemiological significance? What is the prognosis for infection in these subjects? Does rRNA disappear before or after DNA following treatment?[9] A previous study, albeit using a homebrew quantitative assay, found that high level rRNA expression was strongly predictive of clinical signs of active trachoma.[10] It would be interesting to know whether quantitative estimation of rRNA in trachoma subjects will reconcile these findings. Finally, trachoma habitually occurs in settings characterised by poverty and poor access to services and utilities. An ideal test for chlamydial infection would be specific, able to be performed at the point of care and to be interpreted by programme staff with minimal training, cheap and not requiring electricity or expensive technology. The high sensitivity conferred by nucleic acid amplification tests is likely not strictly necessary for community prioritisation and treatment-stopping decisions by programmes. A new test in dipstick format that detects chlamydial lipopolysaccharide antigen is currently undergoing evaluation and may fit the bill here.[11]

Br J Ophthalmol 2007;**91**:271.
doi: 10.1136/bjo.2006.105270

Correspondence to: Robin Bailey, London School of Hygiene & Tropical Medicine Keppel Street, London WC1E 7HT, UK; robin.bailey@lshtm.ac.uk

REFERENCES

1 **Kumaresan J**. Can blinding trachoma be eliminated by 20/20? *Eye*, 2005 Oct, **19**:1067–73.
2 **Bailey RL**, Randomised controlled trial of single-dose azithromycin in treatment of trachoma, *et al. Lancet*, 1993 Aug 21, **342**:453–6.
3 **Thylefors B**, *et al.* A simple system for the assessment of trachoma and its complications. *Bull World Health Organ* 1987;**65**:477–83.
4 **Solomon AW**, *et al.* Trachoma control: a guide for programme managers, WHO/LSHTM/ITI, Geneva 2006.
5 **Baral K**, *et al.* Reliability of clinical diagnosis in identifying infectious trachoma in a low-prevalence area of Nepal. *Bull World Health Organ* 1999;**77**:461–6.
6 **Solomon AW**, *et al.* Mass treatment with single-dose azithromycin for trachoma. *N Engl J Med*, 2004 Nov 4, **351**:1962–71.
7 **Yang JL**, Schachter J, Moncada J, *et al.* Comparison of an rRNA-based and DNA-based nucleic acid amplification test for the detection of *Chlamydia trachomatis* in trachoma. *Br J Ophthalmol* 2007;**91**:293–5.
8 **Aryee E**, *et al.* Plasmid copy number estimation in ocular samples. Proceedings of the 5th meeting of the European Society for Chlamydial Research, Univ of Szeged, 2004:356.
9 **Morre SA**, *et al.* Monitoring of Chlamydia trachomatis infections after antibiotic treatment using RNA detection by nucleic acid sequence based amplification. *Mol Pathol* 1998;**51**:149–54.
10 **Burton MJ**, *et al.* Conjunctival chlamydial 16S ribosomal RNA expression in trachoma: is chlamydial metabolic activity required for disease to develop? *Clin Infect Dis*, 2006 Feb 15, **42**:463–70.
11 **Michel CE**, *et al.* Field evaluation of a rapid point-of-care assay for targeting antibiotic treatment for trachoma control: a comparative study. *Lancet*, 2006 May 13, **367**:1585–90.